Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

Recipharm AB (RECI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Recipharm AB (RECI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Recipharm AB (RECI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Recipharm AB (RECI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The organization's manufacturing segment provides contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm's development and technology segment offers raw material supply, formulation development and development of validated analytical methods, and among others. The organization operates in the UK, Germany, Spain, Italy, Sweden, France, and others. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB (RECI B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Recipharm AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Recipharm AB, Medical Devices Deals, 2012 to YTD 2018 12

Recipharm AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Recipharm AB, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Recipharm Acquires CMO Business from Sanofi for USD60.2 Million 15

Recipharm Acquires Manufacturing Facility from Roche 17

Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 18

Partnerships 20

Kancera and Recipharm Enter into Partnership 20

Klaria Pharma Partners with Recipharm and Clinical Trial Consultants 21

Recipharm Enters into Agreement with Follicum 22

Recipharm Enters into Agreement with Synthonics 23

Kemwell Biopharma Enters into Co-Development Agreement for Monoclonal Antibody Therapeutics 24

Recipharm Enters Into Co-Promotion Agreement With Synthonics 25

Licensing Agreements 26

Recipharm Enters into Licensing Agreement with Altus Formulation 26

Alitair Pharma And Edmond Pharma Enter Into Licensing Agreement For Erdosteine 27

Equity Offering 28

Recipharm Raises USD58.7 Million in Public Offering of Share 28

Recipharm Raises USD99 Million in Rights Offering of Shares 30

Recipharm to Raise USD15.5 Million in Private Placement of Class B Shares 32

Recipharm Raises USD32 Million in Private Placement of Shares 33

Synthonics Raises USD2 Million in Private Placement of Preferred Shares 34

Flamel to Raise USD13.1 Million in Private Placement of Shares 35

Recipharm Announces Underwriters Exercise Of Over-Allotment Option Of IPO For USD 131.37 Million 36

Debt Offering 38

Recipharm Raises USD116.4 Million in Private Placement of Bonds 38

Asset Transactions 39

Serb Acquires Rights for ThyroSafe from Recipharm for USD11.1 Million 39

Acquisition 40

Recipharm Acquires Remaining 26% Stake in Nitin Lifesciences for USD43.8 Million 40

Recipharm Acquires Kemwell Biopharma for USD120 Million 41

Recipharm Acquires Kemwell and Cirrus Pharma from Kemwell Biopharma 42

Recipharm Acquires 74% Stake in Nitin Lifesciences for USD101 Million 44

Recipharm Italia Acquires Mitim for USD75 Million 46

Recipharm Acquires Kaysersberg Pharma from Alcon for USD16.6 Million 47

Recipharm Acquires OnTarget Chemistry for USD1.8 Million 48

Recipharm Acquires Lusomedicameta Sociedade for USD135 Million 49

Recipharm Acquires Corvette Pharma Services from LBO Italia Investimenti for USD160 Million 50

Kemwell Biopharma Acquires Cirrus Pharma 51

Recipharm AB-Key Competitors 52

Recipharm AB-Key Employees 53

Recipharm AB-Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Recent Developments 58

Strategy And Business Planning 58

May 24, 2018: Recipharm invests in Brexit preparations 58

Nov 09, 2017: Recipharm to end operations in two facilities in Sweden 59

Apr 24, 2017: Recipharm opens new GMP suite for clinical trial material 60

Financial Announcements 61

Jul 25, 2018: Recipharm publishes its interim report January-June 2018 61

Feb 22, 2018: Recipharm Reports Fourth Quarter And Full Year 2017 62

Nov 09, 2017: Recipharm: Interim report January-September 2017 64

Jul 25, 2017: Recipharm: Interim report January-June 2017 66

Apr 27, 2017: Recipharm: Interim report January-March 2017 67

Feb 23, 2017: Recipharm: Full Year report January-December 2016 68

Corporate Communications 72

Oct 03, 2018: Recipharm names Tobias Hagglov as Chief Financial Officer 72

May 09, 2018: Recipharm appoints new Chief Financial Officer 73

Feb 26, 2018: Recipharm: Chief Financial Officer to leave Recipharm 74

Feb 14, 2018: Recipharm Appoints President Development Services to Drive End to End Offering 75

Apr 11, 2017: Recipharm appoints Henrik Stenqvist as new Chief Financial Officer 76

Legal and Regulatory 77

Oct 25, 2018: Manufacturing licence restriction at Recipharm, Ashton-u-Lyne, UK facility 77

Sep 13, 2018: Recipharm connects to European Hub for serialisation compliance 78

Product News 79

Oct 09, 2018: Recipharm releases first serialised products to Europe 79

Other Significant Developments 80

Oct 19, 2018: Recipharm continues manufacturing operations in Hoganas, Sweden 80

Jul 02, 2018: Recipharm launches standalone serialisation service 81

Mar 14, 2018: Recipharm completes Blow-fill-seal expansion at Kaysersberg facility 82

Nov 27, 2017: Recipharm equips a further three facilities for US serialisation 83

Oct 23, 2017: Recipharm equips Lisbon facility for US and European serialisation 84

Apr 21, 2017: Recipharm delivers first serialised batch to Saudi Arabia 85

Appendix 86

Methodology 86

About GlobalData 86

Contact Us 86

Disclaimer 86

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Recipharm AB, Medical Devices Deals, 2012 to YTD 2018 12

List of Tables

Recipharm AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Recipharm AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Recipharm AB, Deals By Therapy Area, 2012 to YTD 2018 10

Recipharm AB, Medical Devices Deals, 2012 to YTD 2018 12

Recipharm AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Recipharm Acquires CMO Business from Sanofi for USD60.2 Million 15

Recipharm Acquires Manufacturing Facility from Roche 17

Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 18

Kancera and Recipharm Enter into Partnership 20

Klaria Pharma Partners with Recipharm and Clinical Trial Consultants 21

Recipharm Enters into Agreement with Follicum 22

Recipharm Enters into Agreement with Synthonics 23

Kemwell Biopharma Enters into Co-Development Agreement for Monoclonal Antibody Therapeutics 24

Recipharm Enters Into Co-Promotion Agreement With Synthonics 25

Recipharm Enters into Licensing Agreement with Altus Formulation 26

Alitair Pharma And Edmond Pharma Enter Into Licensing Agreement For Erdosteine 27

Recipharm Raises USD58.7 Million in Public Offering of Share 28

Recipharm Raises USD99 Million in Rights Offering of Shares 30

Recipharm to Raise USD15.5 Million in Private Placement of Class B Shares 32

Recipharm Raises USD32 Million in Private Placement of Shares 33

Synthonics Raises USD2 Million in Private Placement of Preferred Shares 34

Flamel to Raise USD13.1 Million in Private Placement of Shares 35

Recipharm Announces Underwriters Exercise Of Over-Allotment Option Of IPO For USD 131.37 Million 36

Recipharm Raises USD116.4 Million in Private Placement of Bonds 38

Serb Acquires Rights for ThyroSafe from Recipharm for USD11.1 Million 39

Recipharm Acquires Remaining 26% Stake in Nitin Lifesciences for USD43.8 Million 40

Recipharm Acquires Kemwell Biopharma for USD120 Million 41

Recipharm Acquires Kemwell and Cirrus Pharma from Kemwell Biopharma 42

Recipharm Acquires 74% Stake in Nitin Lifesciences for USD101 Million 44

Recipharm Italia Acquires Mitim for USD75 Million 46

Recipharm Acquires Kaysersberg Pharma from Alcon for USD16.6 Million 47

Recipharm Acquires OnTarget Chemistry for USD1.8 Million 48

Recipharm Acquires Lusomedicameta Sociedade for USD135 Million 49

Recipharm Acquires Corvette Pharma Services from LBO Italia Investimenti for USD160 Million 50

Kemwell Biopharma Acquires Cirrus Pharma 51

Recipharm AB, Key Competitors 52

Recipharm AB, Key Employees 53

Recipharm AB, Other Locations 55

Recipharm AB, Subsidiaries 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Recipharm AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person